The 25 references in paper I. Bazaeva Y., I. Poddubnaya V., M. Cherkasova V., N. Orel F., S. Khokhlova V., S. Limareva V., V. Gorbunova A., В. Горбунова А., И. Базаева Я., И. Поддубная В., М. Черкасова В., Н. Орел Ф., С. Лимарева В., С. Хохлова В. (2015) “ЭФФЕКТИВНОСТЬ ПРЕПАРАТА ТРАБЕКТЕДИН В МОНОТЕРАПИИ И КОМБИНИРОВАННЫХ РЕЖИМАХ В ТЕРАПИИ РАСПРОСТРАНЕННОГО РАКА ЯИЧНИКА // THE EFFICIENCY OF TRABECTEDIN IN THE MONOTHERAPY AND COMBINATIONS IN THE TREATMENT OF ADVANCED OVARIAN CANCER” / spz:neicon:modonc:y:2013:i:4:p:14-18

1
World cancer report. IARC Sci Publ. Lyon 2008.
(check this in PDF content)
2
Чиссов В.И., Старинский В.В., Петрова Г.В. Злокачественные заболевания в России в 2011 г. (заболеваемость и смертность). М., 2013.
(check this in PDF content)
3
Урманчеева А.Ф., Мешкова И.Е. Вопросы эпидемиологии и диагностики рака яичников. Практич. онкология. 2000; 4: 7–13.
(check this in PDF content)
4
David-Cordonnier MH, Gajate C, Olmea O et al. DNA and non-DNA targets in the mechanism of action of the antitumor drug trabectedin. Chem Biol 2005; 12: 1201–10.
(check this in PDF content)
5
D'Incalci M, Galmarini CM. A review of trabectedin (ET-743): a unique mechanism of action. Mol Cancer Ther 2010; 9 (8): 2157–63.
(check this in PDF content)
6
Valoti G, Nicoletti MI, Pellegrino A et al. Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts. Clin Cancer Res 1998; 4: 1977–83.
(check this in PDF content)
7
Hendriks HR, Fiebig HH, Giavazzi R et al. High antitumor activity of ET743 against human tumor xenografts from melanoma, non-small-cell lung and ovarian cancer. Ann Oncol 1999; 10: 1233–40.
(check this in PDF content)
8
Sessa C, de Braud F, Perotti A et al. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J Clin Oncol 2005; 20: 1867–74.
(check this in PDF content)
9
Krasner CN, McMeekin DS, Chan S et al. A phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens. Br J Cancer 2007; 97 (12): 1618–24.
(check this in PDF content)
10
Del Campo JM, Roszak A, Bidzinski M et al. Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1,5 mg/m224h or 1,3 mg/m2 3h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer. Ann Oncol 2009; 20: 1794–802.
(check this in PDF content)
11
Del Campo JM, Sessa C, Krasner CN et al. Trabectedin as single agent in relapsed advanced ovarian cancer: results from a retrospective pooled analysis of three phase II trials. Med Oncol 2013; 30: 435.
(check this in PDF content)
12
Ferradina G, Salutari V, Vincenzi B et al. Trabectedin as single agent in the salvage treatment of heavily treated ovarian cancer patients: A retrospective, multicenter study. Gynecol Oncol 2013; 130 (3): 505–10.
(check this in PDF content)
13
Petru E, Kolovetsiou V, Idris T. Prolonged response to trabectedin in a patient with ovarian carcinosarcoma refractory to adjuvant platinumtaxane. J Solid Tumors 2013; 3 (3).
(check this in PDF content)
14
Monk BJ, Herzog T, Kaye S et al. A randomized phase III study of trabectedin with pegylated liposomal doxorubicin versus PLD in relapsed, recurrent ovarian cancer. Proceedings of the 33rd Annual Meeting of the European Society of Medical Oncology. Stockholm 2008. Abstr. LBA3.
(check this in PDF content)
15
Monk BJ, Dalton H, Benjamin I, Tanovi A. Trabectedin as a new chemotherapy option in the treatment of relapsed platinum sensitive ovarian cancer. Curr Pharm Des 2012; 18 (25): 3754–69.
(check this in PDF content)
16
Sehouli J, Alfaro V, González-Martín A. Trabectedin plus pegylated liposomal doxorubicin in the treatment of patients with partially platinumsensitive ovarian cancer: current evidence and future perspectives. Ann Oncol 2012; 23 (3): 556–62.
(check this in PDF content)
17
Poveda A, Vergote I, Tjulandin S et al. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-301 phase III randomized trial. Ann Oncol 2010.
(check this in PDF content)
18
Mabuchi S, Hisamatsu T, Kawase C et al. The activity of Trabectedin as a single agent or in combination with Everolimus for clear cell carcinoma of the ovary. Clin Cancer Res 2011; 17: 4462–73.
(check this in PDF content)
19
Takano M, Ikeda Y, Kudoh K et al. Complete remission of recurrent ovarian clear cell carcinoma by chemotherapy with bevacizumab, trabectedin and oxaliplatin. J Obstet Gynaecol Res 2013; 39 (4): 872–5.
(check this in PDF content)
20
Bevacizumab and Trabectedin ± Carboplatin in Advanced Ovarian Cancer Clinical Trials. Identifier: NCT01735071. Mario Negri Institute for Pharmacol Research 2013. Mario Negri Institute for Pharmacological Research. Collaborators: Pharma Mar, Hoffmann-La Roche.
(check this in PDF content)
21
Monk BJ, Sill M, Walker JL et al. Activity of docetaxel plus trabectedin in reccurent or persistent ovarian and primary peritoneal cancer: A phase II study of the Gynecologic Oncology Group (GOG). J Clin Oncol 2010; 28 (Suppl. 15): 5046.
(check this in PDF content)
22
Sessa C, Cresta S, Noberasco C et al. Phase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumors. Eur J Cancer 2009; 45: 2116–22.
(check this in PDF content)
23
Sessa C, Gallerani E, Del Conte G et al. Phase I dose-finding study of trabectedin (T) in combination with cisplatin (C) in patients (pts) with advanced solid tumors. J Clin Oncol 2011; 29. Abstr. 2517.
(check this in PDF content)
24
Vidal L, Garcia-Martin M, Tan S et al. Phase I combination study of trabectedin and carboplatin in patients with advanced solid tumors. Ann Oncol 2010; 15 (Suppl. 3): 102–1.
(check this in PDF content)
25
Черкасова М.В., Хохлова С.В., Лимарева С.В. и др. Токсичность трабектединсодержащих комбинаций в терапии различных злокачественных новообразований. Соврем. онкология. 2013; 2 (15): 46–50. Пути преодоления резистентности к эрлотинибу у больных немелкоклеточным раком легкого
(check this in PDF content)